BioNTech SE Gross Profit 2019-2021 | BNTX

BioNTech SE annual/quarterly gross profit history and growth rate from 2019 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • BioNTech SE gross profit for the quarter ending June 30, 2021 was $5.331B, a 13312.13% increase year-over-year.
  • BioNTech SE gross profit for the twelve months ending June 30, 2021 was $7.939B, a 8625.27% increase year-over-year.
  • BioNTech SE annual gross profit for 2020 was $0.483B, a 372.9% increase from 2019.
  • BioNTech SE annual gross profit for 2019 was $0.102B, a 24.03% decline from 2018.
  • BioNTech SE annual gross profit for 2018 was $0.134B, a INF% increase from .
BioNTech SE Annual Gross Profit
(Millions of US $)
2020 $483
2019 $102
2018 $134
BioNTech SE Quarterly Gross Profit
(Millions of US $)
2021-06-30 $5,331
2021-03-31 $2,189
2020-12-31 $348
2020-09-30 $71
2020-06-30 $40
2020-03-31 $24
2019-09-30 $27
2019-06-30
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $60.067B $0.551B
BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00